Questions to Ask Your Doctor About Crohn's Disease

Three questions do most of the work in a Crohn's disease appointment: what is my treatment plan and why this one rather than the alternatives, what are my risk factors for the disease getting worse, and how will we check that the treatment is actually working. Ask those in the first minute and the rest of the visit organises itself around them.

Most lists of questions you will find online are exactly that: lists. Twenty questions, no answers, no order, no sense of which ones change what happens next. This guide is built the other way round. For each question it explains why it matters, what a useful answer sounds like, and where in the guidelines it comes from, so you can tell whether you actually got an answer or just a reassuring noise.

The short answer: three questions carry most of the weight

If you only get to ask three things, ask about the plan, the risk and the monitoring. In a recurring pattern across r/CrohnsDisease threads, the most upvoted advice to newly diagnosed people is almost identical each time: ask what the long-term treatment plan is and why that plan over the others, ask how the specialist rates your risk of more severe or progressive disease, and ask what the monitoring plan looks like so a flare gets caught early (r/CrohnsDisease thread, r/CrohnsDisease thread).

That advice lines up unusually well with how specialists are now told to manage Crohn's. The STRIDE-II consensus from the International Organization for the Study of IBD sets out treat-to-target care, in which you and your team agree a target, then reassess at defined intervals and change treatment if the target is not met (Turner 2021). A plan, a risk assessment and a monitoring schedule are the three components of that framework. Asking for them is not asking for a favour; it is asking for the standard of care to be made explicit.

The fourth question, the one people wish they had asked, is usually about timing: when will we know, and what happens if it has not worked by then.

Ask them first, not at the end

Put your questions at the start of the appointment, not when the consultant's hand is on the door handle. The evidence on this is uncomfortable but useful.

Researchers analysed 112 recorded clinical encounters and found that clinicians elicited the patient's agenda in only 40 of them, 36%. In specialty care, which is where gastroenterology sits, it was 10 out of 51 encounters, or 20%. When clinicians did ask, they interrupted the patient after a median of 11 seconds. Patients who were left to finish took a median of 6 seconds to state their concern (Singh Ospina 2019).

Read those two numbers together. Six seconds is all most people need. The problem is not that patients ramble; it is that the opening of the consultation often does not belong to them at all. So take it. A sentence like "before we start, there are three things I need to get answers to today" costs you five seconds and reshapes the next fifteen minutes.

Time pressure is real on the other side of the desk too. A systematic review of consultation length across 67 countries found enormous variation, with average primary care consultations ranging from under 5 minutes in some countries to around 22 minutes in others (Irving 2017). Specialist clinics differ again, but the principle holds: the appointment is shorter than the list of things you want to discuss, so the order matters more than the length of the list.

Does bringing a list of questions actually help?

Yes, but less than the advice columns imply, and that is worth knowing before you arrive with two pages of notes.

A Cochrane review pooled 33 randomised controlled trials from six countries covering 8,244 patients, testing interventions given before consultations to help people get the information they needed. The most common were question checklists and patient coaching. Meta-analysis found a small but statistically significant increase in question asking (standardised mean difference 0.27) and a small increase in patient satisfaction (SMD 0.09). Changes in anxiety after the consultation, patient knowledge and consultation length were small and not statistically significant. The authors concluded that these interventions "produce limited benefits to patients" (Kinnersley 2007).

A later scoping review of 57 studies of question prompt lists found that 88% reported at least one beneficial impact, including increased confidence to ask questions and greater satisfaction with communication, and that this held even for single-page lists with relatively few questions. Patients in those studies consistently said they wanted the list in advance of the visit, not handed to them in the waiting room (Ramlakhan 2023).

The practical reading: a short, prioritised list that you have thought about beforehand is worth more than a long one composed in the car park. Three to five questions, ranked, with the most important first.

Questions about the diagnosis itself

Ask where the disease is, what pattern it has, and what that combination means. Crohn's is not one disease with one script, and the answers here shape everything downstream.

The vocabulary your team uses comes from the Montreal classification, which describes Crohn's by age at diagnosis, location (ileal, colonic, ileocolonic, upper gastrointestinal) and behaviour (non-stricturing and non-penetrating, stricturing, or penetrating), with a separate modifier for perianal disease (Silverberg 2005). If you know your Montreal letters, you can read your own clinic letters.

Useful questions here:

• Where exactly is my Crohn's, and how was that established? A useful answer names segments and the tests behind them, for example inflammation in the terminal ileum seen at colonoscopy and confirmed on biopsy, with MRI showing the extent of small bowel involvement.
• Is my disease inflammatory, stricturing or fistulising at the moment? These behave differently and are treated differently. Perianal fistulising disease in particular has its own management pathway (Feuerstein 2021).
• Is there any perianal involvement? It is easy to leave unasked and important to know.
• How confident are you in the diagnosis, and what would change it? This is the right question when results have been contradictory. In r/IBD, someone described being told they had Crohn's after biopsy, then being told two weeks later that further blood testing was not consistent with Crohn's or ulcerative colitis, and being left unsure what to ask at the follow-up (r/IBD thread). "What are you basing the diagnosis on, and what would make you revisit it" is a fair and answerable question.
• What are my risk factors for a more severe or progressive course? One long-standing community member put it well: everyone fixates on mild, moderate or severe at diagnosis, when what matters for a lifelong condition is how likely it is to progress (r/CrohnsDisease thread).

Questions about treatment: what, why this one, and what if it fails

Ask why this drug rather than the alternatives, what success would look like, and by when. "Why this one" is the question that most often goes unasked and most often reveals the actual reasoning.

Crohn's treatment has moved considerably. The ACG guideline for adults sets out how treatment choice depends on disease severity, location, behaviour and prognostic factors rather than a single ladder everyone climbs (Lichtenstein 2018), and the ECCO therapeutics guideline covers the same ground for European practice (Torres 2020).

The direction of travel matters to your question. The PROFILE trial randomised 386 adults with newly diagnosed active Crohn's disease to either top-down treatment (infliximab plus an immunomodulator from the start) or accelerated step-up treatment. Sustained steroid-free and surgery-free remission at week 48 was reached by 149 of 189 (79%) in the top-down group compared with 29 of 190 (15%) in the accelerated step-up group. There were also fewer adverse events, fewer serious adverse events and fewer complications requiring abdominal surgery in the top-down group. The biomarker the trial was designed to test did not show clinical utility, which the authors reported plainly (Noor 2024).

That single trial does not decide your treatment, and local funding rules, your disease pattern and your own preferences all bear on it. But it does mean "why are we starting here rather than with a biologic" is a current, reasonable question rather than a pushy one. A person newly diagnosed in New Zealand asked r/CrohnsDisease exactly that: biologics had not been presented as an option and they wanted to know whether it was worth raising (r/CrohnsDisease thread). It is.

Questions worth asking about any proposed treatment:

• What is this drug meant to achieve, and by when? A useful answer has a number and a date attached, not just "it should help".
• Why this one rather than the alternatives? Ask what tipped the decision: disease location, prognostic factors, previous treatments, safety considerations, availability.
• What are the realistic chances it works for me? Ask for the rough proportion of people who respond, not just a list of possible side effects.
• What are the risks, and how do they compare with the risk of leaving the inflammation untreated? Both sides of that comparison belong in the answer.
• How is it given, how often, and what does that mean for my week? Infusion time, self-injection, fridge storage, travel.
• What is the plan if it does not work, or stops working? Knowing there is a plan B reduces the sense that everything rides on this one decision.
• Do I need to stay on it when I feel well? Non-adherence is common in IBD: a systematic review of 17 studies found non-adherence rates from 7% to 72%, with most studies reporting 30% to 45%. The factors most consistently linked to it were psychological distress, patients' beliefs about their medications, and discordance between doctor and patient (Jackson 2010). If you have doubts about a drug, saying so is clinically useful information, not a confession.

Never stop, start or change a prescribed medication on your own. If cost, side effects or the practicalities make a treatment hard to keep taking, that is a conversation to have with your IBD team, and it is one they would much rather have than discover months later.

Questions about monitoring: how will we know it is working?

Ask what target you are aiming for, what will be measured, and how often. This is the question that separates a plan from a hope.

STRIDE-II sets symptomatic relief and normalisation of blood and stool markers as short-term targets, and clinical remission plus endoscopic healing as long-term targets, with absence of disability and restored quality of life added as further long-term goals. Transmural healing in Crohn's is not a formal target, but the consensus suggests it can be assessed as a measure of the depth of remission (Turner 2021).

Why this matters in practice: feeling better and being healed are not the same thing, and treating only what you can feel gives worse results. In the CALM trial, 244 people with moderate to severe Crohn's were randomised to tight control, where treatment was escalated based on symptoms plus faecal calprotectin and C-reactive protein, or to clinical management based on symptoms alone. At week 48, mucosal healing was achieved by 56 of 122 (46%) in the tight control group compared with 37 of 122 (30%) in the clinical management group (Colombel 2017). European guidance likewise sets out how biomarkers, endoscopy and imaging are used to monitor IBD rather than relying on symptoms alone (Sturm 2025).

So ask:

• What target are we aiming for, and is it symptom remission, biomarker remission or endoscopic healing?
• What will you measure, and how often? Faecal calprotectin, CRP, full blood count, iron studies, vitamin levels, and at what intervals.
• What calprotectin number would worry you? A threshold you both know in advance turns a result on a portal into information rather than anxiety.
• When is my next colonoscopy or MRI, and what would bring it forward?
• What should make me contact you between appointments, and how? Ask specifically whether there is an IBD nurse advice line and what its response time is.

Questions before starting a biologic or immunosuppressant

Ask about screening, timing, what counts as success, and what to do when you get ill. Starting an immune-modifying drug is the point where preventive care questions stop being optional.

One person described the problem precisely: every time a doctor asks whether they have questions, they get flustered, say no, and then think of a dozen questions afterwards (r/CrohnsDisease thread). If that is you, this is the appointment to write the list for.

• What screening do I need before I start? European guidance covers screening and prevention of infections before and during immune-modifying therapy, including tuberculosis and hepatitis B (Kucharzik 2021).
• Which vaccinations should I have, and do any need to be given before I start? The ACG preventive care guideline in IBD addresses the identification, safety and appropriate timing of vaccinations, and notes that people with IBD often treat their gastroenterologist as their main provider, so these things fall between stools unless someone names them (Farraye 2017).
• Will you check drug levels? The AGA has a guideline specifically on therapeutic drug monitoring in IBD (Feuerstein 2017). Asking whether levels and antibodies will be checked, and when, is a sign you understand that "the drug stopped working" has several different causes.
• What do I do if I get a fever, or an infection, or need antibiotics? Get the answer in writing or in the portal before you need it.
• What about skin checks and cancer surveillance? The ACG preventive care guideline covers screening for osteoporosis, cervical cancer, melanoma and non-melanoma skin cancer (Farraye 2017), and the SCENIC international consensus covers surveillance for dysplasia in IBD (Laine 2015). Ask when your surveillance colonoscopies start and at what interval.
• How long will I be on this? And what, if anything, would prompt stopping or de-escalating.

Questions when a drug stops working

Ask whether the symptoms have been confirmed as inflammation, then whether the drug level has been measured, then what the options are. In that order.

"It stopped working" can mean several different things: the inflammation has broken through, the drug level has fallen or antibodies have developed, a stricture is causing obstructive symptoms that no anti-inflammatory will fix, there is an infection, or the symptoms are IBS-type symptoms happening on top of controlled disease. Each has a different answer, so the first question is diagnostic, not therapeutic.

• Have we confirmed this is active inflammation? Calprotectin, CRP, imaging or endoscopy rather than symptoms alone (Sturm 2025).
• Have my drug levels and antibodies been checked? (Feuerstein 2017)
• Is the plan to optimise this drug or switch class, and why?
• Could this be a stricture rather than active inflammation? Symptoms of obstruction after eating are a different problem from mucosal inflammation.
• If we switch, what does that mean for going back later?

Our guide on tracking Crohn's with a food diary app covers how to record the detail that makes this conversation possible, including the delay between eating and symptoms.

Questions about surgery, if it comes up

Ask what the operation is expected to achieve, what the recovery actually looks like week by week, and what the plan is for preventing recurrence afterwards. Surgery in Crohn's is not a failure of medical treatment, and it is not a cure either.

Fear of surgery and of an ostomy is one of the things people with IBD raise most insistently. In a qualitative preference study, participants elaborated on their uncertainties and fears about the possible need for surgery or an ostomy, the effectiveness and onset of action of their medication, and its long-term effects. When asked to grade what mattered most, they ranked preventing surgery, long-term clinical remission, improved quality of life, urgency and the ability to work as the top five (Schoefs 2023). That study was small, two focus groups with eleven patients plus expert panels, so treat it as a description of what people care about rather than a measurement.

A thread in r/CrohnsDisease from someone preparing for an elective ileocaecal resection collected the practical questions that people said they wished they had asked: laparoscopic or open and what that means for recovery, whether a temporary stoma is planned or possible, expected length of hospital stay and the milestones you have to hit to be discharged, the pain management plan and what medication you go home with, what to eat afterwards, what the common complications look like and whether to call the surgeon or go to the emergency department, what activity to avoid and for how long, and who can visit (r/CrohnsDisease thread). Another person who had had the same operation added the reality check that plans change once the surgeon can see inside, and recovery can take longer than the leaflet suggests.

To that list, add two medical ones:

• What is the plan for preventing recurrence after surgery, and when does monitoring for it start?
• Am I a smoker, and does that change anything? It does. A meta-analysis of 33 studies found that compared with non-smokers, smokers with Crohn's had higher odds of a flare (OR 1.56), flare after surgery (OR 1.97), need for a first operation (OR 1.68) and need for a second operation (OR 2.17), and that the odds among ex-smokers fell towards those of non-smokers after quitting. The authors noted that many people with Crohn's are unaware of this (To 2016). If nobody has raised it with you, raise it yourself, and ask what cessation support is available.

The questions that get skipped

Fatigue, mood, fertility, bones and skin almost never make it onto the agenda unless you put them there. They are not soft extras; they are among the things most likely to shape your year.

Fatigue. A systematic review and meta-analysis of 20 studies found a pooled prevalence of fatigue in adults with IBD of 47% (95% CI 41% to 54%), rising to 72% in active disease and still 47% in remission. Sleep disturbance, anxiety, depression and anaemia were the most commonly reported associated factors (D'Silva 2022). Ask: what could be driving my fatigue, and what can we check for? Iron deficiency is a common and treatable contributor, and there is a European consensus on diagnosing and managing it in IBD (Dignass 2015).

Mood. A meta-analysis of 77 studies including 30,118 patients found a pooled prevalence of anxiety symptoms of 32.1% and depression symptoms of 25.2% in people with IBD, rising to 57.6% and 38.9% respectively in those with active disease (Barberio 2021). Nearly half of patients in the UC Narrative survey did not feel comfortable raising emotional concerns with their physician (Rubin 2021). Asking "what psychological support is available through this service" is a question about your care, not a detour from it.

Fertility and pregnancy. If this is relevant now or might be, ask early rather than when you are already pregnant. In the PIANO study, 1,490 completed pregnancies in women with IBD were followed prospectively. Exposure to biologics, thiopurines or both was not associated with increased congenital malformations, spontaneous abortion, preterm birth, low birth weight or infections in the first year of life. Higher disease activity, by contrast, was associated with spontaneous abortion (hazard ratio 3.41) (Mahadevan 2021). Ask what that means for your specific treatment, and never change a medication yourself on the basis of a study summary.

Joints, eyes, skin and liver. Extraintestinal manifestations are common in IBD and have their own European consensus (Harbord 2016). If you have new joint pain, a painful red eye, mouth ulcers or skin lesions, say so, and ask whether it could be related.

Diet. Ask for a referral rather than a rule. The AGA clinical practice update on diet and nutrition in IBD is clear that no specific diet has consistently been shown to reduce flare rates in adults with IBD, while supporting screening for malnutrition and access to a registered dietitian (Hashash 2024). "Can I be referred to a dietitian with IBD experience" is a more useful question than "what should I cut out". If coffee is your particular question, we have gone through what is known about coffee and Crohn's in detail.

What your team will ask you, and why it is hard to answer

Expect to be asked for numbers you have not been counting. This is where most appointments quietly go wrong, and it is fixable in advance.

A Crohn's review usually opens with some version of: how many bowel movements a day compared with your normal, what the stool has been like, how much urgency, are you woken at night, any blood, how is the abdominal pain and where, has your weight changed, how is your energy, how many doses have you missed, and have you had antibiotics, an infection or anti-inflammatory painkillers recently. Someone who built a tracking app after a Crohn's diagnosis described the trigger for building it as struggling every time doctors or pharmacists asked specific questions about his symptoms (r/IBD thread).

The honest problem is memory. Answering "about the same, I think" is not a good enough basis for a treatment decision, and you deserve better than to be guessing about your own year.

Two low-effort fixes:

1. Count for two weeks before the appointment, not for the whole year. Daily bowel movement count, stool form, urgency, blood yes or no, night-time symptoms yes or no, pain out of ten, and doses missed. Fourteen lines is enough to describe a trend.
2. Bring a one-page summary, not a spreadsheet. Nobody in a fifteen-minute clinic will read 90 days of rows. A paragraph, a count and a trend will be read.

There are validated short tools for this. The IBD-Control questionnaire is 13 items plus a visual analogue scale, was validated in 299 patients with Crohn's disease and ulcerative colitis, and takes a mean of 1 minute 15 seconds to complete (Bodger 2014). If your service uses it, fill it in properly rather than optimistically; it is designed to feed straight into the conversation.

Clairop was built around this specific gap: logging that takes seconds rather than minutes, and a one-page report for a GI visit that shows an activity score, bowel pattern, medication adherence and labs. The method page explains how it handles delayed reactions, which is the part most food diaries get wrong. A notebook and a phone alarm do the same job if you prefer paper.

Which questions belong at which appointment

Not every question fits every visit. This table maps the core questions to the appointment where they will actually get a useful answer.

A worked example: ten minutes, four questions

Here is what front-loading looks like in practice. The details are illustrative, not a real patient.

The situation. Daniel was diagnosed with ileocolonic Crohn's eight months ago and started on a thiopurine. He feels better than he did, but not well: three or four bowel movements most days against his old baseline of one, tired by mid-afternoon, and occasional pain after meals. His fifteen-minute review is on Thursday. He has previously left appointments realising he asked nothing.

Before. For two weeks he keeps fourteen short daily entries: bowel movements, stool form, urgency, blood, night-time symptoms, pain out of ten, doses missed. He writes four questions and stars two.

1. Am I actually in remission, or just better than I was?
2. What is my target, and when do we reassess?
3. My fatigue is the worst part. What could be causing it and what can we test?
4. If this drug is not enough, what is next and when would we decide?

The first minute. He says: "Before we start, there are two things I really need today. One is whether I am in remission or just improved. The other is my fatigue." Then he hands over the one-page summary.

What comes back. His clinician explains that three to four bowel movements a day with post-meal pain is not remission, orders faecal calprotectin and a full blood count with iron studies, and sets out the target explicitly: symptom improvement and a normal calprotectin in the short term, with an endoscopic assessment planned if markers do not settle. A review is booked for eight weeks, with a plan to escalate treatment if the target is missed, discussed and agreed rather than announced.

Why it worked. Nothing here was clever. He asked early, he brought numbers instead of impressions, and he named the symptom that mattered most to him rather than the one he thought was most medical. The fatigue question is the one that would have been cut if he had saved it for the end, and it is the one that prompted the iron studies.

Questions your gastroenterologist genuinely cannot answer

Some questions have no answer, and spending your appointment on them costs you the ones that do.

Why did I get Crohn's? Nobody can tell you why you personally developed it. When someone in r/CrohnsDisease planned to ask about a link between long-term antibiotic use and their Crohn's, the replies were blunt and, on this point, correct: at best a specialist can tell you that certain exposures are associated with risk at a population level, not that any of them caused your disease, and the time would be better spent on the treatment and monitoring plan (r/CrohnsDisease thread).

When will my next flare be? Not predictable. What is answerable is how it will be detected early, which is the monitoring question in different clothes.

Did this specific food cause this specific episode? No test answers this. What a diary can do is generate suspects for a structured challenge, which is a slower and less satisfying process than most people want. We have written about how to tell a food reaction from inflammation in ulcerative colitis, and the same logic applies in Crohn's.

Will I need surgery eventually? Your clinician can describe risk factors and what would change the picture. They cannot give you a yes or no, and a confident yes or no should make you more suspicious, not less.

A good specialist will say "I don't know" to these. That is a sign of a decent clinician, not a bad one.

Myths about asking your doctor questions

Myth: "A long list makes you a difficult patient." What the evidence shows is that question prompts produce modest improvements in question asking and satisfaction, and no meaningful increase in consultation length in the pooled analysis (Kinnersley 2007). A short, ranked list is easier for both sides than an unstructured one.

Myth: "If something were wrong, they would tell me." Preventive care in IBD is known to fall between the gastroenterology team and primary care, which is exactly why there is a guideline telling gastroenterologists to explicitly inform primary care providers of the unique needs of people with IBD (Farraye 2017). Vaccinations, bone density and skin checks often need someone to ask.

Myth: "No symptoms means no inflammation." Treat-to-target care exists precisely because symptoms and inflammation can diverge, and tight control based on biomarkers plus symptoms produced better endoscopic outcomes than symptom-driven management (Colombel 2017, Turner 2021).

Myth: "Asking about a different drug is pushy." Treatment strategy in newly diagnosed Crohn's is an active area of evidence, and a well-conducted trial found substantially better one-year outcomes with early combination treatment (Noor 2024). Asking what shaped the choice is a reasonable question about reasoning.

Myth: "Telling them I skipped doses will annoy them." Non-adherence is reported in roughly a third to nearly half of people in most studies, and doctor-patient discordance was one of the few factors consistently associated with it (Jackson 2010). Hiding it makes a mistaken conclusion about drug failure more likely, not less.

Myth: "Fatigue is just part of having Crohn's, so there is no point raising it." Fatigue is common, but it is also associated with treatable contributors including anaemia, sleep disturbance, anxiety and depression (D'Silva 2022). "Part of the disease" and "worth investigating" are not mutually exclusive.

What to do with the answers afterwards

Repeat the plan back before you leave, then write it down within the hour. Two sentences: what we decided, and what happens next and when.

If you are not sure you have understood, say so in the room. A line like "so just to check I have this right, we are doing X, and if my calprotectin is still above Y in eight weeks we will Z" takes fifteen seconds and catches most misunderstandings. If you can bring someone with you, bring them; a second pair of ears is more reliable than a memory that is trying to process bad news at the same time.

Then ask the logistics question that everybody forgets: how do I contact you between appointments, who answers, and how quickly? IBD nurse advice lines and secure portal messaging are the reason many problems get dealt with in days rather than months.

When not to wait for the next appointment

Some symptoms need contact with your IBD team now, not a question saved for a future clinic. Adjusting your diet or waiting it out is not the right response to any of these.

Contact your IBD team promptly if you have:

• A clear rise in bowel movements above your usual baseline lasting more than a few days
• New or increasing blood in your stool
• Symptoms that wake you at night
• New or worsening abdominal pain, especially pain that comes on after eating with bloating or vomiting, which can suggest obstruction
• Unintended weight loss, or eating much less because of symptoms
• New perianal pain, swelling or discharge
• Feeling unusually tired or breathless, which can be a sign of anaemia
• A recent course of antibiotics, a stomach bug, or regular use of anti-inflammatory painkillers alongside worsening symptoms
• Missed doses of a maintenance treatment, for any reason

Seek urgent, same-day medical help if you have:

• A fever alongside worsening gut symptoms, particularly while on an immune-modifying treatment
• Severe abdominal pain, or a swollen, tender abdomen
• Persistent vomiting or an inability to keep fluids down
• Heavy rectal bleeding, or feeling faint or dizzy when you stand
• Signs of dehydration, such as passing very little urine

These are the symptoms to see a doctor promptly about regardless of when your next appointment is scheduled. For more on living with the condition day to day, browse our Crohn's disease guides.